ProKidney Corp. - Class A Ordinary Shares PROK 深 沪
已收盘 10-03 16:00:00 美东时间
2.74
-0.040
-1.44%
华盛通- 最 高2.94
- 今 开2.78
- 成交量 204.40万股
- 最 低 2.695
- 昨 收 2.78
- 总市值 3.64亿
- 52周最高 7.13
- 市盈率 静 --
- 换手率 1.54%
- 52周最低 0.4603
- 委 比 94.48%
- 总股本 1.33亿
- 历史最高 14.19
- 量 比 1.42
- 振 幅 8.81%
- 历史最低 0.4603
- 每 手 1
- 风险率 0.82%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多SPAC King Chamath Palihapitiya Tells Retail Investors To Stay Away From His New SPAC
Chamath Palihapitiya is back with another SPAC. This time he's telling retail investors to stay away. Here's why.
10-02 23:32
美股牛股 | 网红股OpenDoor一夜飙升近80%！公司高管团队调整
网红股OpenDoor一夜飙升近80%！公司高管团队调整；传埃里森家族正筹备收购，华纳兄弟探索频道大涨超29%>>
09-12 14:23
ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference
ProKidney Corp., a leader in cellular therapeutics for chronic kidney disease, announced that senior management will participate in two upcoming healthcare conferences: the Citi Biopharma Back to School Conference in Boston on September 3, 2025, and the Morgan Stanley Global Healthcare Conference in New York on September 8, 2025. Both events will feature fireside chat sessions available via live webcast. Additional details, including webcast link...
08-27 11:30
Chamath Palihapitiya Returns To SPACs: Past 18 Deals, Investments Average Loss Of 14%
Chamath Palihapitiya is back with a new SPAC. Many investors will remember past SPACs the investor was involved with and the poor performance track record.
08-19 23:53
Watching ProKidney Corp; Zacks Upgrades Stock To Strong Buy
https://www.zacks.com/stock/news/2589077/prokidney-cp-prok-upgraded-to-strong-buy-what-does-it-mean-for-the-stock
07-17 23:52
UBS Maintains Buy on ProKidney, Raises Price Target to $8
UBS analyst Eliana Merle maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target from $4 to $8.
07-15 22:23
Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining ar...
07-15 20:40
ProKidney Confirms Alignment With FDA On Accelerated Approval Pathway For Rilparencel
FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetesFDA also confirmed that the ongoing Phase 3 PROACT 1 study can be used for
07-15 19:31
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
ProKidney Corp. announced alignment with the FDA on the accelerated approval pathway for rilparencel, an autologous cellular therapy for chronic kidney disease (CKD) with type 2 diabetes. The FDA confirmed that the slope of estimated glomerular filtration rate (eGFR) from the Phase 3 PROACT 1 study can serve as a surrogate endpoint for accelerated approval, with nearly half of required patients enrolled. Topline data for the accelerated approval ...
07-15 11:30
ProKidney Enters New $200M Sale Agreement with Jefferies
ProKidney ( ($PROK) ) has issued an update. On July 14, 2025, ProKidney Corp. e...
07-15 05:27
